Joaquin Duato

Pharma

J&J lifts 2025 sales guidance despite looming tariff threat

Even as tariffs start to impact its medtech business, Johnson & Johnson is lifting its sales guidance for 2025 thanks to a recent neuroscience buyout.

Fraiser Kansteiner Apr 15, 2025 11:55am

J&J reduces CEO Duato's pay package by 14% to $24.3M

Mar 12, 2025 11:27am

How J&J CEO broke a stalemate and won Intra-Cellular in M&A push

Feb 7, 2025 11:24am

J&J upholds sales growth confidence as Stelara biosims file in

Jan 22, 2025 11:26am

The top 10 best-paid CEOs in Big Pharma in 2023

Jun 17, 2024 3:00am

J&J hit with talc-related class action lawsuit in New Jersey

May 23, 2024 10:46am